Epizyme Inc (NASDAQ:EPZM) – Equities research analysts at Leerink Swann issued their Q3 2018 earnings per share estimates for shares of Epizyme in a report released on Monday, according to Zacks Investment Research. Leerink Swann analyst G. Porges forecasts that the biopharmaceutical company will earn ($0.90) per share for the quarter. Leerink Swann has a “Outperform” rating and a $22.00 price objective on the stock.
Other analysts also recently issued reports about the company. BidaskClub upgraded Epizyme from a “sell” rating to a “hold” rating in a research note on Saturday, January 6th. ValuEngine upgraded Epizyme from a “sell” rating to a “hold” rating in a research note on Tuesday. Roth Capital initiated coverage on Epizyme in a research note on Thursday, February 1st. They issued a “buy” rating and a $24.00 price target on the stock. Oppenheimer set a $26.00 price target on Epizyme and gave the company a “buy” rating in a research note on Tuesday, December 12th. Finally, Cann restated a “buy” rating and issued a $26.00 price target on shares of Epizyme in a research note on Thursday, November 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $22.73.
Shares of Epizyme (EPZM) traded up $0.65 during mid-day trading on Wednesday, hitting $17.45. The company’s stock had a trading volume of 285,400 shares, compared to its average volume of 480,013. Epizyme has a one year low of $9.30 and a one year high of $20.45. The stock has a market cap of $1,163.95, a P/E ratio of -7.69 and a beta of 2.19.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Teacher Retirement System of Texas acquired a new position in shares of Epizyme in the fourth quarter worth $202,000. Tudor Investment Corp ET AL acquired a new position in shares of Epizyme in the second quarter worth $215,000. Fox Run Management L.L.C. acquired a new position in shares of Epizyme in the third quarter worth $223,000. Bailard Inc. acquired a new position in shares of Epizyme in the fourth quarter worth $251,000. Finally, JGP Global Gestao de Recursos Ltda. acquired a new position in shares of Epizyme in the third quarter worth $292,000. Institutional investors own 85.99% of the company’s stock.
In other Epizyme news, COO Matthew Ros sold 72,264 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $16.63, for a total transaction of $1,201,750.32. Following the sale, the chief operating officer now directly owns 74,867 shares in the company, valued at $1,245,038.21. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 25.20% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/14/research-analysts-issue-forecasts-for-epizyme-incs-q3-2018-earnings-epzm.html.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Get a free copy of the Zacks research report on Epizyme (EPZM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.